Royal Infirmary of Edinburgh, Department of Orthopaedic and Trauma Surgery, 51 Little France Crescent, Edinburgh, United Kingdom, EH16 4SA..
Royal Infirmary of Edinburgh, Department of Orthopaedic and Trauma Surgery, 51 Little France Crescent, Edinburgh, United Kingdom, EH16 4SA.
Injury. 2021 Apr;52(4):1042-1047. doi: 10.1016/j.injury.2020.10.081. Epub 2020 Oct 18.
Percutaneous fixation of Lisfranc injuries is potentially less invasive to traditional open techniques but evidence of any clinical benefit is lacking. The aim of this study is to compare the clinical outcomes of percutaneous reduction and internal fixation (PRIF) of low energy Lisfranc injuries with a matched, control group of patients treated with ORIF.
Over a seven-year period (2012-2019), 16 consecutive patients with a low energy Lisfranc injury (Myerson B2-type) were treated with PRIF. Patient demographics, injury mechanism and radiological outcomes were recorded within a prospectively maintained database at the institution. This study sample was matched for age, sex and mechanism of injury to a control group of 16 patients with similar low energy Lisfranc injuries (Myerson B2-type) treated with ORIF. Clinical outcome was compared using the American Orthopaedic Foot and Ankle Society (AOFAS) midfoot score and Manchester Oxford Foot Questionnaire (MOXFQ).
At a mean follow up of 43 months (95% CI 35.6 - 50.4), both the AOFAS and MOXFQ scores were significantly higher in the PRIF group compared to the control ORIF group (AOFAS 89.1vs 76.4, p=0.03; MOXFQ 10.0 vs 27.6, p=0.03). There were no immediate postoperative complications in either group. There was no radiological evidence of midfoot osteoarthritis in the PRIF group, three patients in the ORIF group developed midfoot osteoarthritis (p=0.2).
PRIF of low energy Lisfranc injures is a safe, minimally invasive technique and is associated with better mid-term clinical outcomes compared to ORIF.
经皮固定 Lisfranc 损伤相对于传统的开放式技术具有潜在的微创优势,但缺乏任何临床获益的证据。本研究旨在比较低能 Lisfranc 损伤经皮复位内固定(PRIF)与接受切开复位内固定(ORIF)治疗的匹配对照组患者的临床结果。
在七年期间(2012-2019 年),16 例连续低能 Lisfranc 损伤(Myerson B2 型)患者接受 PRIF 治疗。在机构内前瞻性维护的数据库中记录患者人口统计学资料、损伤机制和影像学结果。本研究样本与年龄、性别和损伤机制相匹配的 16 例接受 ORIF 治疗的类似低能 Lisfranc 损伤(Myerson B2 型)患者的对照组进行匹配。使用美国矫形足踝协会(AOFAS)中足评分和曼彻斯特牛津足问卷(MOXFQ)比较临床结果。
平均随访 43 个月(95%CI 35.6-50.4)时,PRIF 组的 AOFAS 和 MOXFQ 评分均明显高于对照组(AOFAS 89.1vs 76.4,p=0.03;MOXFQ 10.0vs 27.6,p=0.03)。两组均无术后即刻并发症。PRIF 组无中足骨关节炎的放射学证据,ORIF 组有 3 例患者发生中足骨关节炎(p=0.2)。
低能 Lisfranc 损伤的 PRIF 是一种安全、微创的技术,与 ORIF 相比,具有更好的中期临床结果。